Saturday, October 16, 2021

Novartis hits setback in bid to block Regeneron’s Eylea prefilled syringe as dual lawsuits drag on

Novartis won’t be able to block Regeneron’s popular Eylea prefilled syringe any time soon after a regulatory setback. But the Lucentis maker isn’t giving up on the patent fight that could shift the anti-VEGF competition between the two drugs.

The U.S. International Trade Commission (ITC) on Monday ended (PDF) an investigation into a Novartis complaint that sought to ban imports of Eylea’s prefilled syringe based on alleged patent infringement.

 The termination followed Novartis’ request to withdraw the complaint a month ago—two weeks before a trial in front of an administrative law judge—after the company received an unfavorable opinion from agency staffers.

Instead of pursuing a case at the ITC, Novartis is now making its arguments in federal court. Novartis alleges infringement on the prefilled syringe patent in a lawsuit filed in federal court in New York, while Regeneron has an antitrust complaint against the Swiss pharma in that state.

Before Novartis’ ITC retraction, reviewers at the agency’s Office of Unfair Import Investigations sided with Regeneron, noting that Novartis’ patent and related claims of infringing imports were invalid, according to a redacted document (PDF) prepared before the hearing. The ITC originally opened the case last July.

Staffers recommended to delay any import ban on Eylea prefilled syringes even if Novartis eventually won the case; they raised concerns over public access to the drug as Regeneron switches its production to the vial format.

RELATED: Novartis, Regeneron wage acrimonious patent fight over Eylea’s prefilled syringe

Eylea’s prefilled syringe has quickly gained popularity since its launch in late 2019. It helped the eye drug reach nearly $5 billion in 2020 U.S. sales, up 6.5% despite COVID-19’s hit to the ophthalmology market. By comparison, Lucentis generated CHF 1.4 billion ($1.5 billion) in the U.S. last year, Novartis’ marketing partner Roche reported.

Eylea’s multiple indications, plus its ability to extend treatment intervals, “now in a prefilled syringe for efficiency and throughput in the offices,” make it a top choice for doctors, especially during the pandemic, Regeneron’s commercial chief Marion McCourt said during a conference call in February.

RELATED: Regeneron shoots for longer Eylea dosing interval in diabetic retinopathy with NIH data

Meanwhile, Novartis’ Sandoz generics unit has simultaneously unveiled its phase 3 development plan for an Eylea biosimilar. The new trial, dubbed Mylight, will enroll patients with wet age-related macular degeneration and is aimed to confirm that the biosim has equivalent efficacy and comparable safety to the original Eylea. In a Monday note, SVB Leerink analyst Geoffrey Porges wrote that he expects an approval for the Novartis copycat in early 2024 if everything pans out.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...